Skip to main content

Table 1 Clinical features and prognosis for the AIT-free patients and those receiving AIT

From: Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study

 Missing dataAIT-free patients n = 275Patients receiving AIT during their ICU stay n = 585p value
Male, n (%)1/4166 (61)386 (66)NS
Age, years, median [IQR]3/455 [40–71]59 [48–72]< 0.01
Underlying diseases
 Diabetes, n (%)045 (16)91 (16)NS
 Cardiovascular disease, n (%)0157 (57)342 (58)NS
 Respiratory disease, n (%)044 (16)100 (17)NS
 Renal disease, n (%)024 (9)31 (5)NS
 Liver disease, n (%)0/130 (11)63 (11)NS
 Smoking, n (%)0137 (50)251 (43)NS
 Alcoholism, n (%)0/1128 (47)247 (42)NS
Attributable cause of pancreatitis
 Alcoholism, n (%)080 (29)146 (25)NS
 Gallstones, n (%)097 (35)247 (42)NS
 Post-ERCP, n (%)09 (3)47 (8)< 0.01
 Hypertriglyceridaemia, n (%)026 (9)31 (5)< 0.05
 Cancer, n (%)08 (3)6 (1)NS
 Toxic, n (%)04 (1)17 (3)NS
 Undetermined, n (%)051 (19)96 (16)NS
Clinical presentation on admission
 Pain onset/ICU admission interval, days, median [IQR]02 [1–3]3 [1–8]< 0.001
 Oliguria/anuria, n (%)0120 (44)253 (43)NS
 BISAP score, median [IQR]12/221 [0–1]1 [1–2]< 0.001
 Balthazar score E, n (%)0137 (50)356 (61)< 0.01
Severity criteria on admission
 SOFA score, median [IQR]9/143 [1–5]5 [3–7]< 0.001
 Respiratory failure*, n (%)039 (14)207 (35)< 0.001
 Cardiovascular failure*, n (%)037 (13)202 (35)< 0.001
 Renal failure*, n (%)043 (16)100 (17)NS
 Septic shock, n (%)03 (1)114 (19)< 0.001
 Acute respiratory distress syndrome, n (%)09 (3)53 (9)< 0.01
Therapeutic management on admission
 Vasoactive support, n (%)0/138 (14)207 (35)< 0.001
 Mechanical ventilation, n (%)1/538 (14)187 (32)< 0.001
 Fluid loading, n (%)2/12178 (65)447 (78)< 0.001
 Renal replacement therapy, n (%)1/1016 (6)62 (11)< 0.05
Main treatments between day > 0 and day 30
 Need for red blood cell transfusion, n (%)031 (11)195 (33)< 0.001
 Number of days of mechanical ventilation1/20 [0–0]4 [0–16]< 0.001
 Vasoactive support, n (%)0/159 (21)335 (57)< 0.001
 Renal replacement therapy, n (%)1/142 (15)178 (30)< 0.001
 Duration of RRT, days, median [IQR]14/02 [2–4]7 [2–15]< 0.001
Main complications between day > 0 and day 30
 Acute respiratory distress syndrome, n (%)0/240 (15)201 (34)< 0.001
 Septic shock, n (%)24/474 (2)210 (39)< 0.001
 Pancreatic necrosis, n (%)12/18164 (62)393 (69)< 0.05
 Infected necrosis, n (%)15/295 (2)200 (36)< 0.001
 Gastro-intestinal perforation, n (%)12/324 (1)50 (9)< 0.001
 Vascular thrombosis, n (%)12/2622 (8)86 (15)< 0.01
 Acute mesenteric ischaemia, n (%)12/2825 (10)63 (11)NS
 Intra-abdominal collection, n (%)10/2237 (14)242 (43)< 0.001
 Abdominal compartment syndrome, n (%)12/2617 (6)66 (12)< 0.05
 Haemorrhage, n (%)11/2619 (7)81 (14)< 0.01
 Peritonitis, n (%)12/303 (1)85 (15)< 0.001
 Cholangitis, n (%)15/252 (1)57 (10)< 0.001
 Digestive fistula, n (%)12/281 (1)30 (5)< 0.001
Clinical management between day > 0 and day 30
 Endoscopic necrosectomy, n (%)2/624 (9)152 (26)< 0.001
 Surgical necrosectomy, n (%)0/632 (12)219 (38)< 0.001
 Radiological drainage, n (%)0/68 (3)120 (21)< 0.001
Duration of ICU stay, days, median [IQR]03 [1–6]12 [4–27]< 0.001
ICU readmission, n (%)0/16 (2)50 (9)< 0.001
Hospital mortality rate, n (%)054 (20)143 (24)NS
Time to death, days, median [IQR]01.5 [1–2]12 [2–34]< 0.001
  1. NS non-significant, NA not applicable, ERCP endoscopic retrograde cholangiopancreatography
  2. *According to the definition of the SOFA score